Ingelheim, Germany, 27 September 2012 - Mr. Engelbert Tjeenk Willink, Member of the Board of Managing Directors at Boehringer Ingelheim GmbH and responsible for Marketing and Sales of Prescription Medicines, has decided to leave the Board and the Boehringer Ingelheim Group at the end of 2012. The Shareholders have appointed Mr Allan Hillgrove as new member of the Board of Managing Directors. Mr Hillgrove, 52, will assume responsibility for the Board Division Marketing and Sales Prescription Medicines from 1 January 2013. The Australian national has been part of the Group since 1982 and worked as Head of Established Markets since 2010.
Mr Christian Boehringer, Chairman of the Shareholders Committee and Prof Andreas Barner, Chairman of the Board of Managing Directors stated:
"On behalf of the Shareholders and the Board of Managing Directors, we would like to thank Mr. Engelbert Tjeenk Willink for his many years of dedicated and successful work for the company. We are sorry to see him go and wish him all the best in his future professional and personal life. Mr. Tjeenk Willink has worked with passion and enthusiasm for Boehringer Ingelheim. In his various roles in Ingelheim and abroad, he contributed significantly to the positive development of the Group.
We welcome Mr. Allan Hillgrove to the Board of Managing Directors as an experienced colleague who has got to know the organisation very well in over 30 years. In his various roles he has helped to set the course for sustained growth in recent years. Shareholders and board members are convinced that with this staffing arrangement the Board of Managing Directors will be well equipped for the various challenges that lie ahead for Boehringer Ingelheim and the research-driven pharmaceutical industry worldwide."
Mr. Tjeenk Willink was Head of Marketing for Prescription Medicines at Boehringer Ingelheim GmbH from 2001 to 2005. Before that he acted as Head of Marketing and Sales in Canada, and from 2005 to 2008 he worked as Country Manager of Boehringer Ingelheim Mexico. As a Member of the Board of Managing Directors since 2009, Bert Tjeenk Willink has been responsible for the business area Prescription Medicine and Consumer Health Care.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.